Australia's most trusted
source of pharma news
Tuesday, 26 November 2024
Posted 26 November 2024 AM
The withdrawal of the Climara brand of hormone replacement therapy transdermal patches at the end of last year has left other manufacturers struggling to make up the shortfall.
The TGA has warned of an extended shortage of HRT transdermal patches, which are used in the management of perimenopause and menopause. The PBS-listed brands that are in shortage earned $4.5 million in reimbursements for the financial year 2023-24.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.